$$$Ospreyeye: Charts, Technical Analysis & Japanese Candlestick Patterns$$$

[TraderUsa]

ONCS last quarter report:

It is correct what the author says according to figures reported last financial quarter.


Cash= $8.98MM
Debt= $2.68MM
Net Income= ($1.61MM)

Source: http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9164312-944-203016&type=sect&dcn=0001104659-13-021235

I like the author's conclusion.

OncoSec Medical is a tremendously undervalued company. It has a capitalization of $27MM and a cash flow of $9MM. Besides, it is carrying out several major studies. Immunopulse and Neopulse treatments can provide it with an income of $500MM annually minimum. This enterprise should have a minimum capitalization of $250MM or $2.5 per share.

*Pipeline overview data sourced from OncoSec Medical, all other data sourced from Nasdaq.com, CNN Money as well as the web of the previously mentioned company.

Source: http://www.bolsatrading.eu/2013/04/4-reasons-to-buy-oncosec-medical.html